In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings
暂无分享,去创建一个
Simon Cervenka | James B. Rowe | Franklin I. Aigbirhio | Elijah Mak | John T. O’Brien | J. O'Brien | J. Rowe | S. Cervenka | F. Aigbirhio | E. Mak | Benjamin Hall | Benjamin Hall
[1] J. Olszewski,et al. Progressive Supranuclear Palsy: A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum With Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia , 1964 .
[2] Clifford R. Jack,et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.
[3] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[4] H. Arai,et al. [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[5] O. Garaschuk,et al. Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.
[6] Sylvia Richardson,et al. A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies , 2016, Science Translational Medicine.
[7] M. Freedman,et al. Frontotemporal lobar degeneration , 1998, Neurology.
[8] Michel Goedert,et al. Tau pathology and neurodegeneration , 2013, The Lancet Neurology.
[9] Dean F. Wong,et al. First in-human PET study of 3 novel tau radiopharmaceuticals: [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 , 2015, Alzheimer's & Dementia.
[10] Matthew L Senjem,et al. Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies. , 2016, Brain : a journal of neurology.
[11] Hanna Cho,et al. Subcortical 18 FAV-1451 Binding Patterns in Progressive Supranuclear Palsy , 2016 .
[12] Christopher C Rowe,et al. Tau imaging: early progress and future directions , 2015, The Lancet Neurology.
[13] Bruce R. Rosen,et al. Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data , 2014, NeuroImage.
[14] J. Olszewski,et al. Progressive Supranuclear Palsy: A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum With Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia , 2014, Seminars in Neurology.
[15] Daniel R. Schonhaut,et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.
[16] Yoichi Ishikawa,et al. Longitudinal Assessment of Tau Pathology in Patients with Alzheimer’s Disease Using [18F]THK-5117 Positron Emission Tomography , 2015, PloS one.
[17] Nick C Fox,et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias , 2016, Alzheimer's & Dementia.
[18] Keith A. Johnson,et al. In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain , 2016, The Journal of Neuroscience.
[19] Nick C Fox,et al. The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.
[20] C. Broeckhoven,et al. The role of tau (MAPT) in frontotemporal dementia and related tauopathies , 2004, Human mutation.
[21] Keith A. Johnson,et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.
[22] Hiroko H. Dodge,et al. Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer’s Disease , 2012, Brain Imaging and Behavior.
[23] Elisabeth L. Moussaud-Lamodière,et al. Alpha-synuclein and tau: teammates in neurodegeneration? , 2014, Molecular Neurodegeneration.
[24] A. Joshi,et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. , 2016, Brain : a journal of neurology.
[25] H. Arai,et al. Quinoline and Benzimidazole Derivatives: Candidate Probes for In Vivo Imaging of Tau Pathology in Alzheimer's Disease , 2005, The Journal of Neuroscience.
[26] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.
[27] Hidenao Fukuyama,et al. Global association between cortical thinning and white matter integrity reduction in schizophrenia. , 2014, Schizophrenia bulletin.
[28] C. Duijn,et al. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. , 1999, American journal of human genetics.
[29] I. Dewachter,et al. Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism , 2014, Molecular Neurodegeneration.
[30] Hanna Cho,et al. Subcortical 18F‐AV‐1451 binding patterns in progressive supranuclear palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.
[31] John Hardy,et al. Antiamyloid therapy for Alzheimer's disease--are we on the right road? , 2014, The New England journal of medicine.
[32] Bradford C. Dickerson,et al. Tau PET imaging in aging and early Alzheimer's disease , 2015 .
[33] Nobuyuki Okamura,et al. Introduction and overview of the special issue “Brain imaging and aging”: The new era of neuroimaging in aging research , 2016, Ageing Research Reviews.
[34] Hanna Cho,et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum , 2016, Annals of neurology.
[35] M. Lubberink,et al. Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[36] Keith A. Johnson,et al. Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.
[37] Keith A. Johnson,et al. Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly , 2016, Neurology.
[38] Lin Xie,et al. Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology , 2014, The Journal of Nuclear Medicine.
[39] R. P. Maguire,et al. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[40] Talakad G. Lohith,et al. Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles , 2016, The Journal of Nuclear Medicine.
[41] Clifford R. Jack,et al. Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies , 2015, Neurobiology of Aging.
[42] J. O'Brien,et al. High resolution imaging of the medial temporal lobe in Alzheimer's disease and dementia with Lewy bodies. , 2010, Journal of Alzheimer's disease : JAD.
[43] Guy B. Williams,et al. Longitudinal assessment of global and regional atrophy rates in Alzheimer's disease and dementia with Lewy bodies , 2015, NeuroImage: Clinical.
[44] Kazuhiko Yanai,et al. Advances in the development of tau PET radiotracers and their clinical applications , 2016, Ageing Research Reviews.
[45] John T. O’Brien,et al. This Work Is Licensed under a Creative Commons Attribution 4.0 International License Cortical Tau Load Is Associated with White Matter Hyperintensities , 2022 .
[46] P. Thompson,et al. PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.
[47] Sohee Kim,et al. Selectivity requirements for diagnostic imaging of neurofibrillary lesions in Alzheimer's disease: A simulation study , 2012, NeuroImage.
[48] Ove Almkvist,et al. Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease , 2016, Alzheimer's Research & Therapy.
[49] Yi Su,et al. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease , 2016, Science Translational Medicine.
[50] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[51] Anirvan Ghosh,et al. Specification of synaptic connectivity by cell surface interactions , 2015, Nature Reviews Neuroscience.
[52] P. Bosco,et al. Brain atrophy in Alzheimer’s Disease and aging , 2016, Ageing Research Reviews.
[53] A. Drzezga,et al. Elevated in vivo [18F]‐AV‐1451 uptake in a patient with progressive supranuclear palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.
[54] J. O'Brien,et al. The relationship between hallucinations and FDG-PET in dementia with Lewy bodies , 2016, Brain Imaging and Behavior.
[55] O. Hansson,et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers , 2016, Brain : a journal of neurology.
[56] H. Arai,et al. Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease , 2013, The Journal of Nuclear Medicine.
[57] David T. Jones,et al. AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies , 2016, Annals of neurology.
[58] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[59] J T O'Brien,et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. , 2009, Brain : a journal of neurology.
[60] Guy B. Williams,et al. Structural neuroimaging in preclinical dementia: From microstructural deficits and grey matter atrophy to macroscale connectomic changes , 2017, Ageing Research Reviews.
[61] Clifford R Jack,et al. Rates of cerebral atrophy differ in different degenerative pathologies. , 2006, Brain : a journal of neurology.
[62] A. Lammertsma,et al. Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.
[63] Kazuhiko Yanai,et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. , 2014, Brain : a journal of neurology.
[64] Richard Hollister,et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.
[65] Ming-Rong Zhang,et al. PET Quantification of Tau Pathology in Human Brain with 11C-PBB3 , 2015, The Journal of Nuclear Medicine.
[66] R. Staff,et al. Challenges in the conduct of disease-modifying trials in ad: Practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy , 2009, The journal of nutrition, health & aging.
[67] A. Fagan,et al. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. , 2016, JAMA neurology.
[68] J. Morrison,et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease , 2003, Neurology.
[69] A. Lees,et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. , 2007, Brain : a journal of neurology.
[70] R. Lal,et al. Ion Channel Formation by Tau Protein: Implications for Alzheimer’s Disease and Tauopathies , 2015, Biochemistry.
[71] Gunnar Antoni,et al. Visualization of regional tau deposits using 3H-THK5117 in Alzheimer brain tissue , 2015, Acta neuropathologica communications.
[72] David J. Schlyer,et al. Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[73] Paul Edison,et al. Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia , 2015, Alzheimer's & Dementia.
[74] W. M. van der Flier,et al. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.
[75] N. Volkow,et al. Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[76] Francis Eustache,et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease , 2013, NeuroImage: Clinical.
[77] G. Chételat,et al. Neuroimaging biomarkers in Alzheimer’s disease and other dementias , 2016, Ageing Research Reviews.
[78] Andrew Kertesz,et al. The evolution and pathology of frontotemporal dementia. , 2005, Brain : a journal of neurology.
[79] Daniel R. Schonhaut,et al. PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.
[80] D. Holtzman,et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy , 2015, Annals of clinical and translational neurology.
[81] K. Jellinger,et al. Allocortical neurofibrillary changes in progressive supranuclear palsy , 2004, Acta Neuropathologica.
[82] R. Ransohoff,et al. Regulation of Tau Pathology by the Microglial Fractalkine Receptor , 2010, Neuron.
[83] Bin Zhang,et al. Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.
[84] Anthony J. Spychalla,et al. [18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.
[85] Guy B. Williams,et al. Neuroimaging characteristics of dementia with , 2014 .
[86] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[87] G. Bloom. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. , 2014, JAMA neurology.
[88] Guy B. Williams,et al. Neuroimaging characteristics of dementia with Lewy bodies , 2014, Alzheimer's Research & Therapy.
[89] J. Clarimón,et al. Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies. , 2013, Journal of neuropathology and experimental neurology.
[90] Young T. Hong,et al. [18F]AV‐1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation , 2016, Annals of clinical and translational neurology.
[91] R. Agarwal,et al. CSF tau and amyloid β42 levels in Alzheimer’s disease—A meta-analysis , 2012 .
[92] E. Perry,et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum , 2006, Neurology.
[93] D. Dickson. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration , 1999, Journal of Neurology.
[94] M. Mintun,et al. Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease , 2016, The Journal of Nuclear Medicine.
[95] H. Kolb,et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.
[96] L. Sokoloff,et al. Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. , 1981, Federation proceedings.
[97] C. Jack,et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects , 2010, Alzheimer's & Dementia.
[98] Keith A. Johnson,et al. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. , 2016, JAMA neurology.
[99] Robert A. Dean,et al. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients , 2016, Alzheimer's & Dementia.
[100] Luca Passamonti,et al. Multi-modal MRI investigation of volumetric and microstructural changes in the hippocampus and its subfields in mild cognitive impairment, Alzheimer's disease, and dementia with Lewy bodies , 2017, International Psychogeriatrics.
[101] Kazuhiko Yanai,et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. , 2011, Brain : a journal of neurology.
[102] G. Rabinovici,et al. Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation. , 2016, Journal of Alzheimer's disease : JAD.
[103] Alan J. Thomas,et al. Cortical thickness and VBM-DARTEL in late-life depression. , 2011, Journal of affective disorders.
[104] Jorge Sepulcre,et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.
[105] Rik Ossenkoppele,et al. Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations , 2013, The Journal of Nuclear Medicine.
[106] W. Klunk,et al. [F‐18]AV‐1451 positron emission tomography retention in choroid plexus: More than “off‐target” binding , 2016, Annals of neurology.
[107] Monica Shokeen,et al. New Approaches to Molecular Imaging of Multiple Myeloma , 2016, The Journal of Nuclear Medicine.
[108] Luca Passamonti,et al. Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses , 2017, BMJ Open.
[109] Rupert Lanzenberger,et al. Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology , 2017, The Journal of Nuclear Medicine.
[110] C. Rowe,et al. Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies , 2014, Alzheimer's Research & Therapy.
[111] L. Mosconi,et al. Glucose metabolism in normal aging and Alzheimer’s disease: methodological and physiological considerations for PET studies , 2013, Clinical and Translational Imaging.
[112] H. Rosen,et al. Neuroimaging in frontotemporal dementia , 2013, International review of psychiatry.
[113] L. Murri,et al. CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease , 2008, Brain Research Bulletin.
[114] S Minoshima,et al. Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.
[115] R. Boellaard,et al. Longitudinal amyloid imaging using [11]PIB: Choosing the right method , 2011 .
[116] H. Arai,et al. Characteristics of Tau and Its Ligands in PET Imaging , 2016, Biomolecules.
[117] G. Small,et al. Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment , 2008, The journal of nutrition, health & aging.
[118] Gunnar Antoni,et al. Tracer Kinetic Analysis of (S)-18F-THK5117 as a PET Tracer for Assessing Tau Pathology , 2016, The Journal of Nuclear Medicine.
[119] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[120] Talakad G. Lohith,et al. Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs). , 2016, Journal of medicinal chemistry.
[121] Vincent Doré,et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[122] Janna H. Neltner,et al. Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.
[123] J. O'Brien,et al. Imaging of neuroinflammation in dementia: a review , 2015, Journal of Neurology, Neurosurgery & Psychiatry.
[124] Guy B. Williams,et al. Differential Atrophy of Hippocampal Subfields: A Comparative Study of Dementia with Lewy Bodies and Alzheimer Disease. , 2016, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[125] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.
[126] H. Arai,et al. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.
[127] E. Mandelkow,et al. Tau in physiology and pathology , 2015, Nature Reviews Neuroscience.
[128] J. O'Brien,et al. Neuroinflammation in Lewy body dementia. , 2015, Parkinsonism & related disorders.
[129] Y. Ihara,et al. [A semiquantitative study on Alzheimer neurofibrillary tangles demonstrated immunohistochemically with anti-tau antibodies, in the brains of non-demented and demented old people]. , 1989, No to shinkei = Brain and nerve.
[130] Keith A. Johnson,et al. Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects , 2017, The Journal of Nuclear Medicine.
[131] J. Mazziotta,et al. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. , 2013, Journal of Alzheimer's disease : JAD.
[132] Alan J. Thomas,et al. Regional cerebral blood flow in late-life depression: arterial spin labelling magnetic resonance study , 2012, British Journal of Psychiatry.
[133] Hanna Cho,et al. Tau PET in Alzheimer disease and mild cognitive impairment , 2016, Neurology.
[134] J. Trojanowski,et al. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.
[135] Luca Passamonti,et al. 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy , 2017, Brain : a journal of neurology.
[136] Suzanne L Baker,et al. Reference Tissue–Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging , 2017, The Journal of Nuclear Medicine.
[137] Karl Herholz,et al. Amyloid imaging for dementia in clinical practice , 2015, BMC Medicine.